Cancer Research Technology (CRT; London), the technology commercialization arm of Cancer Research UK, has spun out a new start-up, Acublate, to take forward a next-generation high intensity focused ultrasound (HIFU) surgery device that could offer safety and performance advantages over existing HIFU systems for treating solid tumors.

A new study shows that patients treated with intensity modulated radiation therapy (IMRT), have an increasingly better quality of life post treatment when compared to patients receiving other forms of radiation therapy.